Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that
MRVI - Maravai LifeSciences Holdings, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$5.25
DETAILS
HIGH:
$6.00
LOW:
$4.50
MEDIAN:
$5.25
CONSENSUS:
$5.25
UPSIDE:
19.32%
Stock News
Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that the Company will participate in the following investor conference in June. On June 4, 2026, at 12:50 p.m. Eastern Time, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City, NY. A live webcast of the fireside chat will be on th.
Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable
Maravai LifeSciences Holdings, Inc. is upgraded to Buy, driven by operational restructuring, improved guidance, and sector recovery. MRVI raised 2026 revenue guidance to $205–$215M and adjusted EBITDA to $30–$32M, reflecting robust Q1 results and cost savings. TriLink segment showed 15% YoY growth; restructuring actions are delivering over $65M in annual EBITDA savings.
Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call Transcript
Maravai LifeSciences Q1 Earnings Call Highlights
Maravai LifeSciences NASDAQ: MRVI reported first-quarter fiscal 2026 results that management said marked a “strong start to 2026,” driven by growth at its TriLink segment, steady contribution from Cygnus, and the impact of restructuring actions taken last year.
Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates
Maravai LifeSciences Holdings, Inc. (MRVI) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to a loss of $0.08 per share a year ago.
Maravai LifeSciences Reports First Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2026, together with other business updates. Key Financial Results: Revenue of $65.8 million, Net loss of $(6.4) million, and Adjusted EBITDA of $20.3 million; Returned to positive free cash flow, generating $4.2 million in the quarter; and Inc.
All You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to Buy
Maravai LifeSciences (MRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Baxter International (BAX) Tops Q1 Earnings and Revenue Estimates
Baxter International (BAX) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.55 per share a year ago.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Average Rating of “Hold” from Brokerages
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI - Get Free Report) has been given a consensus recommendation of "Hold" by the five analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company.
Investors Purchase Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI)
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI - Get Free Report) was the target of some unusual options trading activity on Wednesday. Traders bought 1,002 put options on the stock. This represents an increase of 1,791% compared to the typical daily volume of 53 put options. Analysts Set New Price Targets A number of equities analysts have
Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q4 Loss, Beats Revenue Estimates
Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.06 per share a year ago.
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2025, together with other business updates. Key Financial Results: Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million; Annual revenue of $185.7 million, Net loss of.
Maravai LifeSciences (MRVI) to Release Quarterly Earnings on Wednesday
Maravai LifeSciences (NASDAQ: MRVI - Get Free Report) will likely be issuing its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $49.0610 million for the quarter. Parties can find conference call details on the company's upcoming Q4 2025 earning
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2025 financial and operating results after the market close on Wednesday, February 25, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-4136 or 1-203-518-984.
Maravai LifeSciences Target of Unusually High Options Trading (NASDAQ:MRVI)
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI - Get Free Report) was the target of some unusual options trading on Wednesday. Traders acquired 1,002 put options on the company. This represents an increase of approximately 1,791% compared to the average volume of 53 put options. Insider Buying and Selling at Maravai LifeSciences In related news, CEO Bernd
General American Investors Co. Inc. Takes Position in Maravai LifeSciences Holdings, Inc. $MRVI
General American Investors Co. Inc. acquired a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 136,409 shares of the company's stock, valued at approximately $391,000. General American Investors
Price Targets
Maravai Lifesciences price target raised to $6 from $4.50 at Deutsche Bank
$6.00
(was $4.50)
Deutsche Bank
Maravai Lifesciences price target raised to $4.50 from $4 at Wells Fargo
$4.50
(was $3.60)
Brandon Couillard
·
Wells Fargo
Maravai Lifesciences price target lowered to $5 from $10 at Stifel
$5.00
(was $2.27)
Stifel Nicolaus
Maravai Lifesciences price target raised to $10 from $8 at Baird
$10.00
(was $8.87)
Catherine Schulte
·
Robert W. Baird
Deutsche Bank Initiates Coverage On Maravai LifeSciences with Buy Rating, Announces Price Target of $25
$25.00
(was $15.03)
Deutsche Bank
RBC Capital Initiates Coverage On Maravai LifeSciences with Outperform Rating, Announces Price Target of $22
$22.00
(was $12.50)
RBC Capital